Amicus Therapeutics to Present at LEERINK Partners Rare Disease Roundtable

CRANBURY, N.J., Sept. 22, 2015 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a biotechnology company at the forefront of rare and orphan diseases, today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at the LEERINK Partners 4th Annual Rare Disease Roundtable in New York, NY on Wednesday, September 30, 2015 at 2:45 p.m. ET.

A live webcast of the presentation can be accessed through the Investors section of the Amicus Therapeutics corporate web site at http://ir.amicustherapeutics.com/events.cfm, and will be archived for 90 days.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq: FOLD) is a biotechnology company at the forefront of therapies for rare and orphan diseases. The Company is developing novel, first-in-class treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage diseases. Amicus' lead programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, as well as next-generation enzyme replacement therapy (ERT) products for Fabry disease, Pompe disease, and MPS I.

FOLD–G

CONTACT: Investors/Media:
         Amicus Therapeutics
         Sara Pellegrino
         Director, Investor Relations
         [email protected]
         (609) 662-5044

         Media:
         Pure Communications
         Dan Budwick
         [email protected]
         (973) 271-6085

Source: Amicus Therapeutics, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Sabre announces upcoming webcasts of its 2024 Annual Meeting of Stockholders and first quarter 2024 earnings conference call
• Stockholder Alert: Robbins LLP Informs Investors of the Class Action Filed Against Sharecare, Inc. (SHCR)
• Vaxxinity Issues Shareholder Letter